title: Transforming growth factor-beta in human cutaneous leishmaniasis.
abstract: Transforming growth factor (TGF)-beta has several downregulatory functions on the immune system: inhibition of interleukin-2 receptor induction, decrease of interferon-gamma-induced class II antigen expression, inhibition of macrophage activation, as well as cytotoxic and lymphokine-activated killer cell generation. TGF-beta has also been recognized as an important immunoregulator in murine leishmaniasis, for which it increases susceptibility to disease. In the present study we evaluate the involvement of TGF-beta in human leishmaniasis in vitro and in patients with cutaneous leishmaniasis. Human macrophages produce active TGF-beta after infection by Leishmania amazonensis (480 +/- 44.7 pg/ml; mean +/- SEM), L. donovani chagasi (295 +/- 7.6 pg/ml), or L. braziliensis (196 +/- 15.7 pg/ml). When TGF-beta was added to cultures of human macrophages infected with L. braziliensis it led to an increase of approximately 50% in parasite numbers as compared with untreated cultures. Exogenous TGF-beta added to macrophage cultures was able to reverse the effect of interferon-gamma in controlling Leishmania growth. Even at 100 IU/ml interferon-gamma the presence of TGF-beta increases the number of intracellular parasites. On the other hand, TNF-alpha at high concentration (100 IU/ml) totally blunts the suppressive effect of TGF-beta. Immunostaining for TGF-beta was observed in the dermis, produced by fibroblasts and occasionally by inflammatory cells in the biopsies from human leishmaniasis lesions, being present in most of the biopsies taken from patients with early cutaneous leishmaniasis (less than 2 months of ulcer development) and in cases of active mucosal leishmaniasis. Taken together these observations suggest an important role for TGF-beta in human leishmaniasis, with its production by infected macrophages being probably related to parasite establishment in the early stages of the disease.
authors.affiliation: Faculdade de Medicina, Serviço de Imunologia, Universidade Federal da Bahia, Salvador-Bahia, Brazil.
authors.forename: A
authors.initials: A
authors.lastname: Barral
authors.forename: M
authors.initials: M
authors.lastname: Teixeira
authors.forename: P
authors.initials: P
authors.lastname: Reis
authors.forename: V
authors.initials: V
authors.lastname: Vinhas
authors.forename: J
authors.initials: J
authors.lastname: Costa
authors.forename: H
authors.initials: H
authors.lastname: Lessa
authors.forename: A L
authors.initials: AL
authors.lastname: Bittencourt
authors.forename: S
authors.initials: S
authors.lastname: Reed
authors.forename: E M
authors.initials: EM
authors.lastname: Carvalho
authors.forename: M
authors.initials: M
authors.lastname: Barral-Netto
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D006801:Humans; D007150:Immunohistochemistry; D007371:Interferon-gamma / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007892:Leishmania braziliensis / Q000502:physiology; D016773:Leishmaniasis, Cutaneous / Q000378:metabolism* / Q000473:pathology; D008264:Macrophages / Q000187:drug effects / Q000469:parasitology / Q000502:physiology; D016212:Transforming Growth Factor beta / Q000378:metabolism* / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000494:pharmacology
chemical_list: D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma